Insulin Growth Factor-1 as a Predictor for the Progression of Hepatic Disease in Chronic Hepatitis B Virus Infection

Amal Ahmed Mohamed1, Sherief Abd-Elsalam2, *, Mai M. El-Daly3, 4, Noha Kamal5, Salma Mohamed Saed6, Seham Mohamoud7, Hala Ali Abed8, Reda S. Abdelghany9, Shereen Helmy Ahmed10
1 Department of Biochemistry, National Hepatology and Tropical Medicine Research Institution, Cairo, Egypt
2 Department of Tropical Medicine , Tanta University, Tanta, Egypt
3 Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
4 Department of Molecular Biology , National Liver Institute, Menoufia University, Shebin El-Kom, Egypt
5 Theodor Bilharz Research Institute (TBRI), Ministry of Scientific Research and Higher Education
6 Department of Clinical and Chemical Pathology , Faculty of Medicine, Cairo University, Cairo, Egypt
7 Department of Tropical Medicine , El Sahel teaching hospital, Cairo, Egypt
8 Department of Public Health, Faculty of Medicine, Benha University, Banha, Egypt
9 Department of Tropical Medicine , Ahmed Maher Teaching Hospital, Cairo, Egypt
10 Department of Medical Microbiology and Immunology , Faculty of Medicine, Benha University, Banha, Egypt

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 365
Abstract HTML Views: 246
PDF Downloads: 179
ePub Downloads: 90
Total Views/Downloads: 880
Unique Statistics:

Full-Text HTML Views: 190
Abstract HTML Views: 130
PDF Downloads: 114
ePub Downloads: 54
Total Views/Downloads: 488

Creative Commons License
© 2021 Mohamed et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Tropical Medicine , Tanta University, Tanta, Egypt 35127; Tel: 201147773440; E-mail:


Background & Aims:

The aim of this study was to assess IGF-1 in chronic liver diseases associated with HBV infection and describe the impact of liver status on IGF-1 variables.


This cohort study included 348 subjects and conducted between December 2018 and December 2019 at El-Sahel Teaching Hospital, Cairo, Egypt. Subjects were divided into 4 groups: group I included HBV positive hepatocellular carcinoma patients “HCC” (n= 87), group II included HBV positive patients with liver cirrhosis “LC” (n = 87), group III included chronic hepatitis B (CHB) patients with neither HCC nor cirrhosis “CHB” (n = 87) and group IV of healthy volunteers as controls (n = 87). Serum IGF-1 was measured quantitatively using a commercially available enzyme immunoassay.


Serum levels of IGF-1 were measured in each of the 4 groups. The comparison showed marked differences in IGF1-related measures. It was found to be significantly reduced in HCC patients (32.08 ± 9.2 ng/ml), LC patients (50.6±14.1ng/ml) and CHB patients (61.4±14.3 ng/ml) in comparison to healthy subjects (140.4±49.9 ng/ml). The reduction of IGF-1 levels was also statistically significant between both HCC and LC patients and CHB patients also between HCC and LC patients.


Serum IGF-1 levels are significantly reduced with the progression of hepatic disease in HBV patients and it may be a promising serological marker alone or in association with others for prediction of development of liver cirrhosis and HCC in chronic HBV patients.

Keywords: HBV, Cirrhosis, Liver, Cancer, Marker, HCC.